Abstract
An Achromobacter xylosoxidans strain from the Tripoli central hospital produced a unique metallo-β-lactamase, designated TMB-1, which is related to DIM-1 (62%) and GIM-1 (51%). blaTMB-1 was embedded in a class 1 integron and located on the chromosome. The TMB-1 β-lactamase has lower kcat values than both DIM-1 and GIM-1 with cephalosporins and carbapenems. The Km values were more similar to those of GIM-1 than those of DIM-1, with the overall kcat/Km values being lower than those for GIM-1 and DIM-1.
INTRODUCTION
Mobile metallo-β-lactamases (MBLs) are becoming increasingly frequent and pose significant challenges to the treatment of Gram-negative infections worldwide, such that most MBL-producing organisms are only susceptible to colistin (2). These enzymes very efficiently hydrolyze all β-lactams, including carbapenems (with the exception of aztreonam), and the β-lactamase genes most often are located on transferable genetic platforms, namely, either ISCR elements or class 1 integrons sometimes embedded in Tn21- or Tn402-like transposons (22, 24). However, several recently characterized MBL genes have been flanked or associated with ISCR elements, namely, blaSPM-1 with ISCR4, blaNDM-1 with ISCR1, and blaAIM-1 with ISCR16 (6, 21).
Several different MBL-type enzymes have been described, with NDM, IMP, and VIM derivatives being the most widespread (2). The blaIMP-like (17) and blaVIM-like (4) genes have been identified in most clinically relevant bacteria belonging to the Enterobacteriaceae family, in Pseudomonas spp., and in Acinetobacter spp., while blaNDM-1 has mainly been found in Enterobacteriaceae (2, 6, 11, 27). Several other MBLs have been identified in specific geographical locations, including SIM-1 from Acinetobacter baumannii in Korea (8) and KHM-1 from Citrobacter freundii in Japan (16). SPM-1 in Brazil (10, 23), GIM-1 in Germany (3), and AIM-1 in Australia (T. R. Walsh, unpublished data) were all identified in Pseudomonas aeruginosa.
As hospitalized patients are subject to infections by Gram-negative bacteria, and because in Libya adherence to internationally accepted infection control policies is not optimal, we examined the hospital wards and immediate hospital environment for resistance to extended-spectrum cephalosporins. This study reports these findings and further describes the genetic and biochemical characterization of a novel MBL, TMB-1 (for Tripoli metallo-β-lactamase), from Tripoli, Libya.
MATERIALS AND METHODS
Bacterial strains and susceptibility testing.
A total of 38 nonclinical environmental swabs (from hospital wards, cafes, corridors, ventilators, floors, bedside cabinets, oxygen cylinders, electrocardiograph machines, and toilets of intensive care unit wards) were collected from and near four major hospitals in Tripoli. The swabs were transferred to the laboratory in transferring charcoal media, and bacteria were selected by culturing on MacConkey agar (Oxoid, United Kingdom) supplemented with 100 mg/liter vancomycin (to eliminate the growth of Gram-positive bacteria) and 2 mg/liter of ceftazidime to select for strains resistant to extended-spectrum cephalosporins. Isolates were initially identified by the use of Phoenix (Becton and Dickinson) and confirmed by API 20NE (bioMérieux, La Plane, France). The susceptibility tests were performed by Phoenix 100 (Becton Dickinson, Oxford, United Kingdom) and Etest strips (bioMérieux, La Plane, France) and were interpreted by the European Committee on Antimicrobial Susceptibility Testing (http://www.eucast.org/eucast_disk_diffusion_test/breakpoints/).
Phenotypic and molecular detection of MBLs.
Phenotypic MBL detection was carried out using the new MBL Etest strips with meropenem as a substrate (bioMérieux, La Plane, France), and the results were interpreted according to the manufacturer's instructions.
Identification of blaTMB-1, PCR experiments, and cloning.
Molecular screening was performed on all isolates targeting the conserved region of class 1 integrons, ISCR elements, and Tn21- and Tn402-like transposons (Table 1). The PCR conditions were undertaken as previously described (24). Where possible, PCR products from the conserved region of class 1 integrons were run on 1% (wt/vol) agarose gels, purified, and subcloned into Escherichia coli TOP10 cells (Invitrogen, Life Technologies Ltd., Paisley, United Kingdom) and sequenced using the primers listed in Table 1. All of the PCR products were run on 1% (wt/vol) agarose gel, purified, and sequenced using an automated sequencer (AB 377; Perkin-Elmer, CT).
Table 1.
Primers used in this study
Gene target | Primer no.a | Primer name | Primer sequence | Reference or source |
---|---|---|---|---|
Integrase gene | 1 | VAF | GCC TGT TCG GTT CGT AAG CT | 22 |
Quaternary ammonium compound | 2 | QacR | CGG ATG TTG CGA TTA CTT CG | 22 |
TMB-1 | 3 | Trip-1F61 | GCC AAC GAA GAA ATA CCC GC | This study |
TMB-1 | 4 | Trip2-10 | TGG GCT AGG TTA CAC TGG TG | This study |
TMB-1 | 5 | Trip617R | TTC TAG CGG ATT GTG GCC AC | This study |
TMB-1 | 6 | Trip2 | CAA GGA GCT CAT TCA AAGG | This study |
TMB-1 | 7 | Trip1 | GGA GCA GGC AAG GAG CT | This study |
TMB-1 | 8 | Trip75 | ACC CGG ATT GGA AGT TGA GG | This study |
TMB-1 | 9 | Trip1 FF | TGA TCA GTG GCC ACA ATC CG | This study |
TMB-1 | 10 | Trip1 F | CGG ATT GTG GCC ACT GAT CA | This study |
dhfrA | 11 | dhfrA 1F | CGA AGA ATG GAG TTA TCG GG | This study |
dhfrA | 12 | dhfrA 1R | GTT AGA GGC GAA GTC TTG GG | This study |
dhfrA | 13 | dhfrA 1FF | CCC AAG ACT TCG CCT CTA AC | This study |
aac6II | 14 | aac6II R | GGC GTC GGC TTG AAT GAG TT | This study |
aac6II | 15 | aac6II F | AAG TGG CAG CAA CGG ATT CG | This study |
aac6II | 16 | aac6II FR | GAA TCC GTT GCT GCC ACT TG | This study |
aac6II | 17 | aac6II FF | CAA CTC ATT CAA GCC GAC GC | This study |
Oxa-4 | 18 | oxa-4-FR | CAC TTA TGG CAT TTG ATG CG | This study |
Oxa-4 | 19 | oxa-4-F | CGC ATC AAA TGC CAT AAG TG | This study |
Tn21 | NA | Tn21 A | GGG GTC GTC TCA GAA AAC GG | 22 |
Tn21 | NA | Tn21 B | GGA AAA TAA AGC ACG CTA AG | 22 |
Tn402 | NA | Tn402F | GTC GTT TTC AGA AGA CGG C | 24 |
Tn402 | NA | Tn402R | CTA TGC TCA ATA CTC GTG TGC | 24 |
ISCR1 | NA | CRFF | GGT TGC AAC GAC TCA AGCG | 6 |
ISCR1 | NA | RECR1 | CAC TCG TTT ACC GCT CAA GC | 6 |
The primer numbers are the same as those used in Fig. 1.
Conjugation experiments.
The conjugational transfer of antibiotic resistance to the laboratory strain E. coli J53 (azide resistant) and Pseudomonas aeruginosa PAO1 (rifampin resistant) was carried out on blood agar without selection. After 18 h, the mixed cultures were washed from the plates, suspended in saline, and plated onto MacConkey agar containing sodium azide (100 μg/ml) and ceftazidime (2 μg/ml) or rifampin (50 μg/ml) and ceftazidime (2 μg/ml). Ceftazidime-resistant colonies were screened for blaTMB-1 by the primers listed in Table 1.
Hybridization.
Gel plugs of chromosomal DNA were prepared and restricted with S1 nuclease as previously described (27). Hybridization was performed in a gel. Briefly, the gel was dried for 5 h at 50°C and then rehydrated in double-distilled water for 5 min before 30-min incubations in a denaturing solution (0.5 M NaOH, 1.5 M NaCl) and neutralizing solution (0.5 M Tris-HCl, pH 7.5, 1.5 M NaCl) at room temperature. The gel was then prehybridized at 65°C using prehybridizing solution (20 ml; 6× SSC [1× SSC is 0.15 M NaCl plus 0.015 M sodium citrate], 0.1% [wt/vol] polyvinylpyrrolidone 400, 0.1% [wt/vol] Ficoll, 0.1% [wt/vol] bovine serum albumin [BSA; Cohn fraction V], 0.5% [wt/vol] SDS, and 150 μg/ml denatured calf thymus DNA) for at least 4 h before adding the probe. The 32P-labeled probe was added for a minimum of 8 h at 65°C before being removed with washes of 2× SSC, 0.1% SDS for 1 h, followed by 0.1× SSC, 0.1% SDS for 3 h; both washes were performed at 65°C. blaTMB-1 probes were labeled with 32P by using a random primer technique (Stratagene, La Jolla, CA).
Purification of TMB-1.
To negate posttranslational modification in an unnatural host, TMB-1 was purified directly from strain AES301, which was grown overnight at 37°C in Terrific broth (Sigma, St. Louis, MO). TMB-1 was purified from the periplasm (15), followed by ion exchange (Q-Sepharose HP column; Pharmacia, GE Healthcare, United Kingdom) and gel filtration (Superdex 200 column; GE Healthcare) using 50 mM Tris (pH 7.2), 100 μM ZnCl2, 0.02% (wt/vol) sodium azide, with or without NaCl, as the buffer system. Fractions containing TMB-1 were analyzed using nitrocefin with or without EDTA, and the fractions were analyzed by SDS-PAGE (Invitrogen, CA). TMB-1 was concentrated to 1.94 mg/ml using ultrafiltration (Millipore, MA).
Kinetics assays.
Steady-state kinetics were performed at 25°C in a spectrophotometer (SpectramaxPlus; Molecular Devices) using 96-well plates (BD Falcon UV microplates; BD Biosciences) (15). All substrates were tested as duplicates using 50 mM HEPES buffer, pH 7.2, 100 μM ZnCl2, 0.02% NaN3, and 0.1 mg/ml bovine serum albumin (Sigma-Aldrich) as a buffer system. The kinetic data were analyzed by nonlinear regression (GraphPad Software, San Diego, CA).
Nucleotide sequence accession number.
The full sequence of the 3-kb class 1 integron reported in the present study has been submitted to the EMBL/GenBank and assigned nucleotide sequence accession number FR771847.
RESULTS AND DISCUSSION
Analysis of swabs from Tripoli hospitals.
All swabs yielded isolates capable of growing on 2 μg/ml ceftazidime and 10 μg/ml vancomycin. All isolates were screened for class 1 integrons and mobile genetic elements (Tn21, Tn402, and ISCR elements), and 4 out of 38 isolates were positive for class 1 integrons: one Achromobacter xylosoxidans isolate (two integrons of ∼3 kb), one Stenotrophomonas maltophilia isolate (2.5 kb), and two isolates of Citrobacter freundii, each positive for a class integron of 1 kb. None of the isolates were positive for Tn21, Tn402, and ISCR elements. A. xylosoxidans AES301 displayed the following MIC profile: imipenem, 2 μg/ml; meropenem, 4 μg/ml; cefepime, 16 μg/ml; ceftazidime, 8 μg/ml; cefotaxime, 32 μg/ml; aztreonam, 16 μg/ml; amikacin, 8 μg/ml; gentamicin, 8 μg/ml; ciprofloxacin, 1 μg/ml; and colistin, 0.5 μg/ml. All isolates that grew on media containing ceftazidime were screened by the MBL Etest strip to detect the presence of MBLs. Apart from the S. maltophilia isolate (which naturally carries the L1 MBL) (26), the only other MBL-positive isolate was an A. xylosoxidans strain, designated AES301, possessing the class 1 integron, and it was investigated further.
Genetic analysis of carbapenem resistance in A. xylosoxidans strain AES301.
The sequencing analysis of the class 1 integron PCR products from A. xylosoxidans AES301 revealed two nearly identical integrons, the first possessing the gene cassette dhfrA4-aacA4-blaOXA-4 and the second integron containing the gene cassette blaTMB-1-aacA4-blaOXA-4 (Fig. 1). The carbapenem resistance could not be mated to either E. coli DH5α or P. aeruginosa PAO1 recipients (data not shown), suggesting that the blaTMB-1 integron is chromosomally located. This inference was supported by Southern hybridization data using the blaTMB-1 gene as a probe, which was back blotted to the A. xylosoxidans AES301 chromosome (data not shown) even though it produced several plasmids.
Fig 1.
Genetic context of two class 1 integrons found in A. xylosoxidans and the primers used to sequence the structures. (A) Class 1 integron consisting of the gene cassettes containing dhfrA4, aacA4, blaOXA-4, and the qacEΔ/sulL fusion. (B) Class 1 integron consisting of the gene cassettes containing blaTMB-1, aacA4, blaOXA-4, and qacEΔ/sulL. The white ellipses represent the hybrid promoter from intI1. The black ellipses represent the 59-bp elements at the start of each gene cassette. The arrows depict primers used to amplify and sequence the integrons, and the sequences are given in Table 1.
The TMB-1 gene contains 735 nucleotides and encodes a protein of 245 amino acids possessing all of the key motifs of Ambler class B β-lactamase. At the amino acid level, TMB-1 was most closely related to DIM-1 (62%) and GIM-1 (51%) and showed only 48, 31, and 29% identity to IMP-1, VIM-2, and NDM-1, respectively (Fig. 2A). TMB-1 also possesses virtually the same key residues as DIM-1 that make up the zinc binding residues and the secondary residues supporting the active sites, including the putative loop used to facilitate the binding of β-lactams during hydrolysis (Fig. 2A). A secondary structural comparison of TMB-1 to VIM-2 shows that TMB-1 possesses the key zinc binding residues for B1 MBLs, namely, His116, His118, and His196 (zinc 1) and Asp120, Cys221, and His263 (zinc 2) (Fig. 2A). The most noticeable difference between TMB-1 and VIM-2 is a gap in the N terminus of the TMB-1 protein just before the beginning of the first β-sheet (β1 in Fig. 2B). This gap in TMB-1 is situated just prior to the flapping loop of VIM-2, which has been shown to facilitate the binding and hydrolysis of substrates (1). Further, there are several amino acid differences in this region, namely (comparing VIM-2 to TMB-1), Q60S, S61R, F62V, D63E, A66G, V67L, and a gap at position 65. This region is also diverse between VIM-2 and VIM-7, where it has been suggested that it contributes to a more flexible flapping loop (1). Interestingly, DIM-1 possesses the same sequence as TMB-1 in this region, with the exception of the gap and the amino acid changes N63E and F65W (12 and data not shown). An additional gap in TMB-1 between β7 and β8 compared to the VIM-2 sequence is also observed (Fig. 2B).
Fig 2.
(A) Comparison of amino acid sequence of the β-lactamase TMB-1 to those of other acquired MBLs (DIM-1, GIM-1, IMP-1, KMH-1, NDM-1, VIM-1, SPM-1, and SIM-1) and several naturally occurring MBLs (IND-1 from Chryseobacterium indologenes, JOHN-1 from Flavobacterium johnsoniae, SLB-1 from Shewanella livingstonensis, and SFB-1 from Shewanella frigidimarina). Shaded amino acids are those conserved with TMB-1. β-Lactamase numbering was according to the BBL nomenclature (5). (B) Secondary structure of TMB-1 compared to that of VIM-2. The β-strands and α-helixes are indicated above the TMB-1 sequence. The conserved residues are indicated in black. The conservative amino acid substitutions are boxed. The figure was obtained using ESPript software (http://espript.ibcp.fr/ESPript/ESPript/).
Kinetic properties of TMB-1.
The kinetic properties of TMB-1 were compared to those of DIM-1 and GIM-1 (Table 2) and are broadly similar, with the exception of the rate of turnover of substrates (kcat values) (Table 2). The Km values for TMB-1 are similar to those of DIM-1 and GIM-1 for the penicillins and cephalosporins but are larger for meropenem, indicating that TMB-1 binds meropenem comparatively weakly. The kcat values for TMB-1 are similar between the pencillins and GIM-1 but are markedly less (30- to 260-fold) than those for both DIM-1 and GIM-1 for cefoxitin, cefuroxime, and ceftazidime (Table 2). TMB-1 also possesses lower kcat values for the carbapenems (2- to 36-fold) compared to those of DIM-1 and GIM-1. These data further show that the efficiency of the enzyme (kcat/Km) is lower for the cephalosporins and carbapenems (Table 2). Such differences in kinetic values are interesting, given that TMB-1 and DIM-1 are similar and that their sequences in the VIM-2 flapping loop (15) are nearly identical, further suggesting that the reasons for these kinetic differences lie elsewhere in the TMB-1 structure (Fig. 2B).
Table 2.
Steady-state kinetic constants of TMB-1, DIM-1, and GIM-1
Compound | Steady-state kinetic constants ofc: |
||||||||
---|---|---|---|---|---|---|---|---|---|
TMB-1 |
DIM-1a |
GIM-1b |
|||||||
kcat (s−1) | Km (μM) | kcat/Km (s−1/μM) | kcat (s−1) | Km (μM) | kcat/Km (s−1/μM) | kcat (s−1) | Km (μM) | kcat/Km (s−1/μM) | |
Ampicillin | 3.3 | 27 | 0.122 | 20 | 110 | 0.182 | 3.3 | 20 | 0.165 |
Piperacillin | 3.3 | 72 | 0.046 | NR | NR | NR | 6.9 | 69 | 0.1 |
Cefoxitin | 0.3 | 69 | 0.004 | 8 | 20 | 0.4 | 8.3 | 206 | 0.04 |
Cefuroxime | 0.1 | 9 | 0.011 | NR | NR | NR | 5.9 | 7 | 0.843 |
Ceftazidime | 0.07 | 31 | 0.002 | 3 | 50 | 0.06 | 18 | 31 | 0.58 |
Ertapenem | 0.4 | 31 | 0.013 | NR | NR | NR | NR | NR | NR |
Imipenem | 1.7 | 200 | 0.009 | 35 | 80 | 0.438 | 27 | 287 | 0.094 |
Meropenem | 1.4 | 75 | 0.019 | 50 | 10 | 5 | 2.7 | 25 | 0.108 |
Aztreonam | <0.01 | ND | ND | <0.01 | ND | ND | ND | ND | ND |
Achromobacter is not the most important pathogen, although a growing number of reports indicate that it is capable of causing urinary tract infections (20), ocular infections (13), and the contamination of dialysis (25) and ultrasound equipment (9), and it can cause additional complications in cystic fibrosis patients (7, 14). Interestingly, although AES301 carrying TMB-1 was found in a ward surface swab, the same strain could not be identified from a clinical source; however, in Libya clinical diagnostic microbiology laboratories may not scrutinize strains to the species level. To date, only two cases of MBL genes (both blaVIM-2) have been reported from Achromobacter spp., from Greece (19) and Korea (18), and both were carried by class 1 integrons. This is the first MBL reported from Libya, and being a new subclass, it provides further evidence of the structural heterogeneity of this group of β-lactamases.
ACKNOWLEDGMENTS
A.E.S. was supported by an overseas scholarship from the Libyan government. Project money for the work in Cardiff was provided by the European Commission FP7 grant PAR. Ø.S. was supported by a grant from the Northern Norway Regional Health Authority.
Janis Weeks provided technical assistance at Cardiff University.
Footnotes
Published ahead of print 30 January 2012
REFERENCES
- 1. Borra PS, et al. 2011. Structural and computational investigations of VIM-7: insights into the substrate specificity of VIM metallo-beta-lLactamases. J. Mol. Biol. 411:174–189 [DOI] [PubMed] [Google Scholar]
- 2. Bush K, Fisher JF. 2011. Epidemiological expansion, structural studies and clinical challenges of new beta-lactamases from Gram-negative bacteria. Annu. Rev. Microbiol. 65:455–478 [DOI] [PubMed] [Google Scholar]
- 3. Castanheira M, Toleman MA, Jones RN, Schmidt FJ, Walsh TR. 2004. Molecular characterization of a beta-lactamase gene, blaGIM-1, encoding a new subclass of metallo-beta-lactamase. Antimicrob. Agents Chemother. 48:4654–4661 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4. Cornaglia G, Mazzariol A, Lauretti L, Rossolini GM, Fontana R. 2000. Hospital outbreak of carbapenem-resistant Pseudomonas aeruginosa producing VIM-1, a novel transferable metallo-beta-lactamase. Clin. Infect. Dis. 31:1119–1125 [DOI] [PubMed] [Google Scholar]
- 5. Galleni M, et al. 2001. Standard numbering scheme for class B beta-lactamases. Antimicrob. Agents Chemother. 45:660–663 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6. Kumarasamy KK, et al. 2010. Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological study. Lancet Infect. Dis. 10:597–602 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7. Lambiase A, et al. 2011. Achromobacter xylosoxidans respiratory tract infection in cystic fibrosis patients. Eur. J. Clin. Microbiol. Infect. Dis. 30:973–980 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8. Lee K, et al. 2005. Novel acquired metallo-beta-lactamase gene, bla(SIM-1), in a class 1 integron from Acinetobacter baumannii clinical isolates from Korea. Antimicrob. Agents Chemother. 49:4485–4491 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9. Olshtain-Pops K, et al. 2011. An outbreak of Achromobacter xylosoxidans associated with ultrasound gel used during transrectal ultrasound guided prostate biopsy. J. Urol. 185:144–147 [DOI] [PubMed] [Google Scholar]
- 10. Picao RC, Poirel L, Gales AC, Nordmann P. 2009. Diversity of beta-lactamases produced by ceftazidime-resistant Pseudomonas aeruginosa isolates causing bloodstream infections in Brazil. Antimicrob. Agents Chemother. 53:3908–3913 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11. Poirel L, et al. 2000. Characterization of VIM-2, a carbapenem-hydrolyzing metallo-beta-lactamase and its plasmid- and integron-borne gene from a Pseudomonas aeruginosa clinical isolate in France. Antimicrob. Agents Chemother. 44:891–897 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12. Poirel L, Rodriguez-Martinez JM, Al Naiemi N, Debets-Ossenkopp YJ, Nordmann P. 2010. Characterization of DIM-1, an integron-encoded metallo-beta-lactamase from a Pseudomonas stutzeri clinical isolate in the Netherlands. Antimicrob. Agents Chemother. 54:2420–2424 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13. Reddy AK, Garg P, Shah V, Gopinathan U. 2009. Clinical, microbiological profile and treatment outcome of ocular infections caused by Achromobacter xylosoxidans. Cornea 28:1100–1103 [DOI] [PubMed] [Google Scholar]
- 14. Ridderberg W, Bendstrup KE, Olesen HV, Jensen-Fangel S, Norskov-Lauritsen N. 2011. Marked increase in incidence of Achromobacter xylosoxidans infections caused by sporadic acquisition from the environment. J. Cyst. Fibros. 10:466–469 [DOI] [PubMed] [Google Scholar]
- 15. Samuelsen O, Castanheira M, Walsh TR, Spencer J. 2008. Kinetic characterization of VIM-7, a divergent member of the VIM metallo-beta-lactamase family. Antimicrob. Agents Chemother. 52:2905–2908 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16. Sekiguchi J, et al. 2008. KHM-1, a novel plasmid-mediated metallo-beta-lactamase from a Citrobacter freundii clinical isolate. Antimicrob. Agents Chemother. 52:4194–4197 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17. Senda K, et al. 1996. PCR detection of metallo-beta-lactamase gene (blaIMP) in gram-negative rods resistant to broad-spectrum beta-lactams. J. Clin. Microbiol. 34:2909–2913 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18. Shin KS, et al. 2005. Imipenem-resistant Achromobacter xylosoxidans carrying blaVIM-2-containing class 1 integron. Diagn. Microbiol. Infect. Dis. 53:215–220 [DOI] [PubMed] [Google Scholar]
- 19. Sofianou D, Markogiannakis A, Metzidie E, Pournaras S, Tsakris A. 2005. VIM-2 metallo-beta-lactamase in Achromobacter xylosoxidans in Europe. Eur. J. Clin. Microbiol. Infect. Dis. 24:854–855 [DOI] [PubMed] [Google Scholar]
- 20. Tena D, Gonzalez-Praetorius A, Perez-Balsalobre M, Sancho O, Bisquert J. 2008. Urinary tract infection due to Achromobacter xylosoxidans: report of 9 cases. Scand. J. Infect. Dis. 40:84–87 [DOI] [PubMed] [Google Scholar]
- 21. Toleman MA, Bennett PM, Walsh TR. 2006. ISCR elements: novel gene-capturing systems of the 21st century? Microbiol. Mol. Biol. Rev. 70:296–316 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 22. Toleman MA, Biedenbach D, Bennett DM, Jones RN, Walsh TR. 2005. Italian metallo-beta-lactamases: a national problem? Report from the SENTRY Antimicrobial Surveillance Programme. J. Antimicrob. Chemother. 55:61–70 [DOI] [PubMed] [Google Scholar]
- 23. Toleman MA, et al. 2002. Molecular characterization of SPM-1, a novel metallo-beta-lactamase isolated in Latin America: report from the SENTRY antimicrobial surveillance programme. J. Antimicrob. Chemother. 50:673–679 [DOI] [PubMed] [Google Scholar]
- 24. Toleman MA, Vinodh H, Sekar U, Kamat V, Walsh TR. 2007. blaVIM-2-harboring integrons isolated in India, Russia, and the United States arise from an ancestral class 1 integron predating the formation of the 3′ conserved sequence. Antimicrob. Agents Chemother. 51:2636–2638 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 25. Turgutalp K, Kiykim A, Ersoz G, Kaya A. 2011. Fatal catheter-related bacteremia due to Alcaligenes (Achromobacter) xylosoxidans in a hemodialysis patient. Int. Urol. Nephrol. [Epub ahead of print.] doi:10.1007/s11255-011-0003-1 [DOI] [PubMed] [Google Scholar]
- 26. Walsh TR, et al. 1994. Sequence analysis of the L1 metallo-beta-lactamase from Xanthomonas maltophilia. Biochim. Biophys. Acta 1218:199–201 [DOI] [PubMed] [Google Scholar]
- 27. Walsh TR, Weeks J, Livermore DM, Toleman MA. 2011. Dissemination of NDM-1 positive bacteria in the New Delhi environment and its implications for human health: an environmental point prevalence study. Lancet Infect. Dis. 11:355–362 [DOI] [PubMed] [Google Scholar]